Location of cervical cancer and an example of normal and abnormal cells
|Classification and external resources|
Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Early on, typically no symptoms are seen. Later symptoms may include abnormal vaginal bleeding, pelvic pain, or pain during sexual intercourse. While bleeding after sex may not be serious, it may also indicate the presence of cervical cancer.
Human papillomavirus (HPV) infection appears to be involved in the development of more than 90% of cases; most people who have had HPV infections, however, do not develop cervical cancer. Other risk factors include smoking, a weak immune system, birth control pills, starting sex at a young age, and having many sexual partners, but these are less important. Cervical cancer typically develops from precancerous changes over 10 to 20 years. About 90% of cervical cancer cases are squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. Diagnosis is typically by cervical screening followed by a biopsy. Medical imaging is then done to determine whether or not the cancer has spread.
HPV vaccines protect against between two and seven high-risk strains of this family of viruses and may prevent up to 90% of cervical cancers. As a risk of cancer still exists, guidelines recommend continuing regular Pap smears. Other methods of prevention include: having few or no sexual partners and the use of condoms. Cervical cancer screening using the Pap smear or acetic acid can identify precancerous changes which when treated can prevent the development of cancer. Treatment of cervical cancer may consist of some combination of surgery, chemotherapy, and radiotherapy. Five year survival rates in the United States are 68%. Outcomes, however, depend very much on how early the cancer is detected.
Worldwide, cervical cancer is both the fourth-most common cause of cancer and the fourth-most common cause of death from cancer in women. In 2012, an estimated 528,000 cases of cervical cancer occurred, with 266,000 deaths. This is about 8% of the total cases and total deaths from cancer. About 70% of cervical cancers occur in developing countries. In low-income countries, it is the most common cause of cancer death. In developed countries, the widespread use of cervical screening programs has dramatically reduced rates of cervical cancer. In medical research, the most famous cell line known as HeLa was developed from cervical cancer cells of a woman named Henrietta Lacks.
- 1 Signs and symptoms
- 2 Causes
- 3 Diagnosis
- 4 Prevention
- 5 Treatment
- 6 Prognosis
- 7 Epidemiology
- 8 History
- 9 Society and culture
- 10 References
- 11 Further reading
- 12 External links
Signs and symptoms
The early stages of cervical cancer may be completely free of symptoms. Vaginal bleeding, contact bleeding (one most common form being bleeding after sexual intercourse), or (rarely) a vaginal mass may indicate the presence of malignancy. Also, moderate pain during sexual intercourse and vaginal discharge are symptoms of cervical cancer. In advanced disease, metastases may be present in the abdomen, lungs, or elsewhere.
Symptoms of advanced cervical cancer may include: loss of appetite, weight loss, fatigue, pelvic pain, back pain, leg pain, swollen legs, heavy vaginal bleeding, bone fractures, and/or (rarely) leakage of urine or feces from the vagina. Bleeding after douching or after a pelvic exam is a common symptom of cervical cancer.
Infection with some types of HPV is the greatest risk factor for cervical cancer, followed by smoking. Other risk factors include human immunodeficiency virus. Not all of the causes of cervical cancer are known, however, and several other contributing factors have been implicated.
Of the 150-200 types of HPV known, 15 are classified as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82), three as probable high-risk (26, 53, and 66), and 12 as low-risk (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108).
Genital warts, which are a form of benign tumor of epithelial cells, are also caused by various strains of HPV. However, these serotypes are usually not related to cervical cancer. It is common to have multiple strains at the same time, including those that can cause cervical cancer along with those that cause warts.
Infection with HPV is generally believed to be required for cervical cancer to occur.
Cigarette smoking, both active and passive, increases the risk of cervical cancer. Among HPV-infected women, current and former smokers have roughly two to three times the incidence of invasive cancer. Passive smoking is also associated with increased risk, but to a lesser extent.
Smoking has also been linked to the development of cervical cancer. Smoking can increase the risk in women a few different ways, which can be by direct and indirect methods of inducing cervical cancer. A direct way of contracting this cancer is a smoker has a higher chance of CIN3 occurring which has the potential of forming cervical cancer. When CIN3 lesions lead to cancer, most of them have the assistance of the HPV virus, but that is not always the case, which is why it can be considered a direct link to cervical cancer. Heavy smoking and long-term smoking seem to have more of a risk of getting the CIN3 lesions than lighter smoking or not smoking at all. Although smoking has been linked to cervical cancer, it aids in the development of HPV which is the leading cause of this type of cancer. Also, not only does it aid in the development of HPV, but also if the woman is already HPV-positive, she is at an even greater likelihood of contracting cervical cancer.
Long-term use of oral contraceptives is associated with increased risk of cervical cancer. Women who have used oral contraceptives for 5 to 9 years have about three times the incidence of invasive cancer, and those who used them for 10 years or longer have about four times the risk.
Having many pregnancies is associated with an increased risk of cervical cancer. Among HPV-infected women, those who have had seven or more full-term pregnancies have around four times the risk of cancer compared with women with no pregnancies, and two to three times the risk of women who have had one or two full-term pregnancies.
The Pap smear can be used as a screening test, but is false negative in up to 50% of cases of cervical cancer. Confirmation of the diagnosis of cervical cancer or precancer requires a biopsy of the cervix. This is often done through colposcopy, a magnified visual inspection of the cervix aided by using a dilute acetic acid (e.g. vinegar) solution to highlight abnormal cells on the surface of the cervix. Medical devices used for biopsy of the cervix include punch forceps, SpiraBrush CX, SoftBiopsy, or Soft-ECC.
Colposcopic impression, the estimate of disease severity based on the visual inspection, forms part of the diagnosis.
Further diagnostic and treatment procedures are loop electrical excision procedure and conization, in which the inner lining of the cervix is removed to be examined pathologically. These are carried out if the biopsy confirms severe cervical intraepithelial neoplasia.
Often before the biopsy, the doctor asks for medical imaging to rule out other causes of woman's symptoms. Imaging modalities including ultrasound, CT scan and MRI have been used to different extent to look for alternating disease/spread of tumor/effect on adjacent structures. Typically, they appear as heterogeneous mass in the cervix.
Cervical intraepithelial neoplasia, the potential precursor to cervical cancer, is often diagnosed on examination of cervical biopsies by a pathologist. For premalignant dysplastic changes, cervical intraepithelial neoplasia grading is used.
The naming and histologic classification of cervical carcinoma precursor lesions has changed many times over the 20th century. The World Health Organization classification system was descriptive of the lesions, naming them mild, moderate, or severe dysplasia or carcinoma in situ (CIS). The term, cervical intraepithelial neoplasia (CIN) was developed to place emphasis on the spectrum of abnormality in these lesions, and to help standardise treatment. It classifies mild dysplasia as CIN1, moderate dysplasia as CIN2, and severe dysplasia and CIS as CIN3. More recently, CIN2 and CIN3 have been combined into CIN2/3. These results are what a pathologist might report from a biopsy.
These should not be confused with the Bethesda system terms for Pap smear (cytopathology) results. Among the Bethesda results: Low-grade Squamous Intraepithelial Lesion (LSIL) and High-grade Squamous Intraepithelial Lesion (HSIL). An LSIL Pap may correspond to CIN1, and HSIL may correspond to CIN2 and CIN3, however they are results of different tests, and the Pap smear results need not match the histologic findings.
Histologic subtypes of invasive cervical carcinoma include the following: Though squamous cell carcinoma is the cervical cancer with the most incidence, the incidence of adenocarcinoma of the cervix has been increasing in recent decades.
- squamous cell carcinoma (about 80-85%)
- adenocarcinoma (about 15% of cervical cancers in the UK)
- adenosquamous carcinoma
- small cell carcinoma
- neuroendocrine tumour
- glassy cell carcinoma
- villoglandular adenocarcinoma
Noncarcinoma malignancies which can rarely occur in the cervix include melanoma and lymphoma. The FIGO stage does not incorporate lymph node involvement in contrast to the TNM staging for most other cancers.
For cases treated surgically, information obtained from the pathologist can be used in assigning a separate pathologic stage, but is not to replace the original clinical stage.
Cervical cancer is staged by the International Federation of Gynecology and Obstetrics (FIGO) staging system, which is based on clinical examination, rather than surgical findings. It allows only these diagnostic tests to be used in determining the stage: palpation, inspection, colposcopy, endocervical curettage, hysteroscopy, cystoscopy, proctoscopy, intravenous urography, and X-ray examination of the lungs and skeleton, and cervical conization.
Checking the cervix by the Papanicolaou test, or Pap smear, for cervical cancer has been credited with dramatically reducing the number of cases of and mortality from cervical cancer in developed countries. Pap smear screening every 3–5 years with appropriate follow-up can reduce cervical cancer incidence up to 80%. Abnormal results may suggest the presence of precancerous changes, allowing examination and possible preventive treatment. The treatment of low-grade lesions may adversely affect subsequent fertility and pregnancy. Personal invitations encouraging women to get screened are effective at increasing the likelihood they will do so. Educational materials also help increase the likelihood women will go for screening, but they are not as effective as invitations.
According to the 2010 European guidelines, the age at which to start screening ranges between 20 and 30 years of age, "but preferentially not before age 25 or 30 years", and depends on burden of the disease in the population and the available resources.
In the United States, screening is recommended to begin at age 21, regardless of age at which a woman began having sex or other risk factors. Pap tests should be done every three years between the ages of 21 and 65. In women over the age of 65, screening may be discontinued if no abnormal screening results were seen within the previous 10 years and no history of CIN 2 or higher exists. HPV vaccination status does not change screening rates. Screening can occur every 5 years between ages 30 and 65 when a combination of cervical cytology screening and HPV testing is used and this is preferred. However, it is acceptable to screen this age group with a Pap smear alone every 3 years. Screening is not beneficial before age 25 as the rate of disease is low. Screening is not beneficial in women older than 60 years if they have a history of negative results.
Liquid-based cytology is another potential screening method. Although it was probably intended to improve on the accuracy of the Pap test, its main advantage has been to reduce the number of inadequate smears from around 9% to around 1%. This reduces the need to recall women for a further smear. The United States Preventive Services Task Force supports screening every 5 years in those who are between 30 and 65 years when cytology is used in combination with HPV testing.
Pap smears have not been as effective in developing countries. This is in part because many of these countries have an impoverished health care infrastructure, too few trained and skilled professionals to obtain and interepret Pap smears, uninformed women who get lost to follow-up, and a lengthy turn-around time to get results. These realities have resulted in the investigation of cervical screening approaches that use fewer resources and offer rapid results such as visual inspection with acetic acid or HPV DNA testing.
Barrier protection and/or spermicidal gel use during sexual intercourse decreases cancer risk. Condoms offer protection against cervical cancer. Evidence on whether condoms protect against HPV infection is mixed, but they may protect against genital warts and the precursors to cervical cancer. They also provide protection against other STIs, such as HIV and Chlamydia, which are associated with greater risks of developing cervical cancer.
Condoms may also be useful in treating potentially precancerous changes in the cervix. Exposure to semen appears to increase the risk of precancerous changes (CIN 3), and use of condoms helps to cause these changes to regress and helps clear HPV. One study suggests that prostaglandin in semen may fuel the growth of cervical and uterine tumors and that affected women may benefit from the use of condoms.
Abstinence also prevents HPV infection.
Two HPV vaccines (Gardasil and Cervarix) reduce the risk of cancerous or precancerous changes of the cervix and perineum by about 93% and 62%, respectively. The vaccines are between 92% and 100% effective against HPV 16 and 18 up to at least 8 years.
HPV vaccines are typically given to women age 9 to 26 as the vaccine is only effective if given before infection occurs. The vaccines have been shown to be effective for at least 4 to 6 years, and they are believed to be effective for longer; however, the duration of effectiveness and whether a booster will be needed is unknown. The high cost of this vaccine has been a cause for concern. Several countries have considered (or are considering) programs to fund HPV vaccination.
Since 2010, young women in Japan have been eligible to receive the cervical cancer vaccination for free. In June 2013, the Japanese Ministry of Health, Labor and Welfare mandated that, before administering the vaccine, medical institutions must inform women that the Ministry does not recommend it. However, the vaccine is still available at no cost to Japanese women who choose to accept the vaccination.
The treatment of cervical cancer varies worldwide, largely due to access to surgeons skilled in radical pelvic surgery, and the emergence of "fertility-sparing therapy" in developed nations. Because cervical cancers are radiosensitive, radiation may be used in all stages where surgical options do not exist.
Microinvasive cancer (stage IA) may be treated by hysterectomy (removal of the whole uterus including part of the vagina). For stage IA2, the lymph nodes are removed, as well. Alternatives include local surgical procedures such as a loop electrical excision procedure or cone biopsy. For 1A1 disease, a cone biopsy (cervical conization) is considered curative.
If a cone biopsy does not produce clear margins (findings on biopsy showing that the tumor is surrounded by cancer free tissue, suggesting all of the tumor is removed), one more possible treatment option for women who want to preserve their fertility is a trachelectomy. This attempts to surgically remove the cancer while preserving the ovaries and uterus, providing for a more conservative operation than a hysterectomy. It is a viable option for those in stage I cervical cancer which has not spread; however, it is not yet considered a standard of care, as few doctors are skilled in this procedure. Even the most experienced surgeon cannot promise that a trachelectomy can be performed until after surgical microscopic examination, as the extent of the spread of cancer is unknown. If the surgeon is not able to microscopically confirm clear margins of cervical tissue once the woman is under general anesthesia in the operating room, a hysterectomy may still be needed. This can only be done during the same operation if the woman has given prior consent. Due to the possible risk of cancer spread to the lymph nodes in stage 1b cancers and some stage 1a cancers, the surgeon may also need to remove some lymph nodes from around the uterus for pathologic evaluation.
A radical trachelectomy can be performed abdominally or vaginally and opinions are conflicting as to which is better. A radical abdominal trachelectomy with lymphadenectomy usually only requires a two- to three-day hospital stay, and most women recover very quickly (about six weeks). Complications are uncommon, although women who are able to conceive after surgery are susceptible to preterm labor and possible late miscarriage. Wait at least one year is generally recommended before attempting to become pregnant after surgery. Recurrence in the residual cervix is very rare if the cancer has been cleared with the trachelectomy. Yet, women are recommended to practice vigilant prevention and follow-up care including Pap screenings/colposcopy, with biopsies of the remaining lower uterine segment as needed (every 3–4 months for at least 5 years) to monitor for any recurrence in addition to minimizing any new exposures to HPV through safe sex practices until one is actively trying to conceive.
Early stages (IB1 and IIA less than 4 cm) can be treated with radical hysterectomy with removal of the lymph nodes or radiation therapy. Radiation therapy is given as external beam radiotherapy to the pelvis and brachytherapy (internal radiation). Women treated with surgery who have high-risk features found on pathologic examination are given radiation therapy with or without chemotherapy to reduce the risk of relapse.
Larger early-stage tumors (IB2 and IIA more than 4 cm) may be treated with radiation therapy and cisplatin-based chemotherapy, hysterectomy (which then usually requires adjuvant radiation therapy), or cisplatin chemotherapy followed by hysterectomy. When cisplatin is present, it is thought to be the most active single agent in periodic diseases.
Advanced-stage tumors (IIB-IVA) are treated with radiation therapy and cisplatin-based chemotherapy. On June 15, 2006, the US Food and Drug Administration approved the use of a combination of two chemotherapy drugs, hycamtin and cisplatin, for women with late-stage (IVB) cervical cancer treatment. Combination treatment has significant risk of neutropenia, anemia, and thrombocytopenia side effects.
For surgery to be curative, the entire cancer must be removed with no cancer found at the margins of the removed tissue on examination under a microscope. This procedure is known as exenteration.
Prognosis depends on the stage of the cancer. The chance of a survival rate around 100% is high for women with microscopic forms of cervical cancer. With treatment, the five-year relative survival rate for the earliest stage of invasive cervical cancer is 92%, and the overall (all stages combined) five-year survival rate is about 72%. These statistics may be improved when applied to women newly diagnosed, bearing in mind that these outcomes may be partly based on the state of treatment five years ago when the women studied were first diagnosed.
With treatment, 80 to 90% of women with stage I cancer and 60 to 75% of those with stage II cancer are alive 5 years after diagnosis. Survival rates decrease to 30 to 40% for women with stage III cancer and 15% or fewer of those with stage IV cancer 5 years after diagnosis.
According to the International Federation of Gynecology and Obstetrics, survival improves when radiotherapy is combined with cisplatin-based chemotherapy.
As the cancer metastasizes to other parts of the body, prognosis drops dramatically because treatment of local lesions is generally more effective than whole-body treatments such as chemotherapy.
Interval evaluation of the woman after therapy is imperative. Recurrent cervical cancer detected at its earliest stages might be successfully treated with surgery, radiation, chemotherapy, or a combination of the three. About 35% of women with invasive cervical cancer have persistent or recurrent disease after treatment.
Average years of potential life lost from cervical cancer are 25.3. Around 4,600 women were projected to die in 2001 in the US of cervical cancer, and the annual incidence was 13,000 in 2002 in the US, as calculated by SEER. Thus, the ratio of deaths to incidence is about 35.4%.
Regular screening has meant that precancerous changes and early-stage cervical cancers have been detected and treated early. Figures suggest that cervical screening is saving 5,000 lives each year in the UK by preventing cervical cancer. About 1,000 women per year die of cervical cancer in the UK. All of the Nordic countries have cervical cancer-screening programs in place. Pap smear was integrated into clinical practice in the Nordic countries in the 1960s.
Worldwide, cervical cancer is both the fourth-most common cause of cancer and deaths from cancer in women. In 2012, 528,000 cases of cervical cancer were estimated to have occurred, with 266,000 deaths. It is the second-most common cause of female-specific cancer after breast cancer, accounting for around 8% of both total cancer cases and total cancer deaths in women. About 80% of cervical cancers occur in developing countries.
An estimated 12,900 new cervical cancers and 4,100 cervical cancer deaths will occur in the United States in 2015. In the United States, it is the eight-most common cancer of women. The median age at diagnosis is 48. Hispanic women are significantly more likely to be diagnosed with cervical cancer than the general population. In 1998, about 12,800 women were diagnosed in the US and about 4,800 died. In 2014, an estimated 12,360 new cases were expected to be diagnosed, and about 4,020 were expected to die of cervical cancer. Among cancers of the female reproductive tract it is less common than endometrial cancer and ovarian cancer. The rates of new cases in the United States was 7 per 100,000 women in 2004. Cervical cancer deaths decreased by approximately 74% in the last 50 years, largely due to widespread Pap smear screening. The annual direct medical cost of cervical cancer prevention and treatment prior to introduction of the HPV vaccine was estimated at $6 billion.
In the European Union, about 34,000 new cases per year and over 16,000 deaths due to cervical cancer occurred in 2004.
Cervical cancer is the 12th-most common cancer in women in the UK (around 3,100 women were diagnosed with the disease in 2011), and accounts for 1% of cancer deaths (around 920 died in 2012). With a 42% reduction from 1988-1997, the NHS-implemented screening programme has been highly successful, screening the highest-risk age group (25–49 years) every 3 years, and those ages 50–64 every 5 years.
In Canada, an estimated 1,300 women will have been diagnosed with cervical cancer in 2008 and 380 will have died.
Australia had 734 cases of cervical cancer (2005). The number of women diagnosed with cervical cancer has dropped on average by 4.5% each year since organised screening began in 1991 (1991–2005). Regular twice-yearly Pap tests can reduce the incidence of cervical cancer up to 90% in Australia, and save 1,200 Australian women from dying from the disease each year.
In India,the number of people with uterine cervix cancer are rising, but overall the age-adjusted rates are decreasing. Improvement of education in the female population has improved the survival of women with cancers of uterine cervix.
- 400 BCE - Hippocrates noted that cervical cancer was incurable
- 1925 - Hinselmann invented the colposcope
- 1928 - Papanicolaou developed the Papanicolaou technique
- 1941 - Papanicolaou and Traut: Pap smear screening began
- 1946 - Aylesbury spatula was developed to scrape the cervix, collecting the sample for the Pap smear
- 1951 - First successful in-vitro cell line, HeLa, derived from biopsy of cervical cancer of Henrietta Lacks
- 1976 - Harald zur Hausen and Gisam found HPV DNA in cervical cancer and genital warts; Hausen later won the Nobel Prize for his work
- 1988 - Bethesda System for reporting Pap results was developed
- 2006 - First HPV vaccine was approved by the FDA
Epidemiologists working in the early 20th century noted that cervical cancer behaved like a sexually transmitted disease. In summary:
- Cervical cancer was noted to be common in female sex workers.
- It was rare in nuns, except for those who had been sexually active before entering the convent. (Rigoni in 1841)
- It was more common in the second wives of men whose first wives had died from cervical cancer.
- It was rare in Jewish women.
- In 1935, Syverton and Berry discovered a relationship between RPV (Rabbit Papillomavirus) and skin cancer in rabbits. (HPV is species-specific and therefore cannot be transmitted to rabbits)
These historical observations suggested that cervical cancer could be caused by a sexually transmitted agent. Initial research in the 1940s and 1950s attributed cervical cancer to smegma (e.g. Heins et al. 1958). During the 1960s and 1970s it was suspected that infection with herpes simplex virus was the cause of the disease. In summary, HSV was seen as a likely cause because it is known to survive in the female reproductive tract, to be transmitted sexually in a way compatible with known risk factors, such as promiscuity and low socioeconomic status. Herpes viruses were also implicated in other malignant diseases, including Burkitt's lymphoma, Nasopharyngeal carcinoma, Marek's disease and the Lucké renal adenocarcinoma. HSV was recovered from cervical tumour cells.
A description of human papillomavirus (HPV) by electron microscopy was given in 1949, and HPV-DNA was identified in 1963. It was not until the 1980s that HPV was identified in cervical cancer tissue. It has since been demonstrated that HPV is implicated in virtually all cervical cancers. Specific viral subtypes implicated are HPV 16, 18, 31, 45 and others.
In work that was initiated in the mid 1980s, the HPV vaccine was developed, in parallel, by researchers at Georgetown University Medical Center, the University of Rochester, the University of Queensland in Australia, and the U.S. National Cancer Institute. In 2006, the U.S. Food and Drug Administration (FDA) approved the first preventive HPV vaccine, marketed by Merck & Co. under the trade name Gardasil.
Society and culture
In Australia, Aboriginal women are more than five times more likely to die from cervical cancer than non-Aboriginal women, suggesting that Aboriginal women are less likely to have regular Pap tests. There are several factors that may limit indigenous women from engaging in regular cervical screening practices, including sensitivity in discussing the topic in Aboriginal communities, embarrassment, anxiety and fear about the procedure. Difficulty in accessing screening services (for example, transport difficulties) and a lack of female GPs, trained pap smear providers and trained female Aboriginal Health Workers are also issues.
The Australian Cervical Cancer Foundation (ACCF), founded in 2008, promotes 'women’s health by eliminating cervical cancer and enabling treatment for women with cervical cancer and related health issues, in Australia and in developing countries.' Ian Frazer, one of the developers of the Gardasil cervical cancer vaccine, is the scientific advisor to ACCF. Janette Howard, the wife of former Australian Prime Minister John Howard, was diagnosed with cervical cancer in 1996, and first spoke on her battle with the disease in 2006.
A 2007 survey of 3,076 American women found only 40% had heard of HPV infection and less than half of those knew it causes cervical cancer.
- "Cervical Cancer Treatment (PDQ®)". NCI. 2014-03-14. Retrieved 24 June 2014.
- "Defining Cancer". National Cancer Institute. Retrieved 10 June 2014.
- Tarney, CM; Han, J (2014). "Postcoital bleeding: a review on etiology, diagnosis, and management.". Obstetrics and Gynecology International 2014: 192087. PMID 25045355.
- Kumar V, Abbas AK, Fausto N, Mitchell RN (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier. pp. 718–721. ISBN 978-1-4160-2973-1.
- Kufe, Donald (2009). Holland-Frei cancer medicine. (8th ed.). New York: McGraw-Hill Medical. p. 1299. ISBN 9781607950141.
- World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.12. ISBN 9283204298.
- Dunne, EF; Park, IU (Dec 2013). "HPV and HPV-associated diseases.". Infectious Disease Clinics of North America 27 (4): 765–78. doi:10.1016/j.idc.2013.09.001. PMID 24275269.
- "Cervical Cancer Treatment (PDQ®)". National Cancer Institute. 2014-03-14. Retrieved 25 June 2014.
- "FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV". U.S. Food and Drug Administration. 10 December 2014. Retrieved 8 March 2015.
- "Human Papillomavirus (HPV) Vaccines". National Cancer Institute. 2011-12-29. Retrieved 25 June 2014.
- Tran, NP; Hung, CF; Roden, R; Wu, TC (2014). "Control of HPV infection and related cancer through vaccination.". Recent Results in Cancer Research 193: 149–71. doi:10.1007/978-3-642-38965-8_9. PMID 24008298.
- "Cervical Cancer Prevention (PDQ®)". National Cancer Institute. 2014-02-27. Retrieved 25 June 2014.
- World Health Organization (February 2014). "Fact sheet No. 297: Cancer". Retrieved 2014-06-24.
- "SEER Stat Fact Sheets: Cervix Uteri Cancer". NCI. Retrieved 18 June 2014.
- World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 1.1. ISBN 9283204298.
- Canavan TP, Doshi NR (2000). "Cervical cancer". Am Fam Physician 61 (5): 1369–76. PMID 10735343.
- Jr, Charles E. Carraher (2014). Carraher's polymer chemistry (Ninth ed.). Boca Raton: Taylor & Francis. p. 385. ISBN 9781466552036.
- Nanda, Rita (2006-06-09). "Cervical cancer". MedlinePlus Medical Encyclopedia. National Institutes of Health. Retrieved 2007-12-02.
- "Cervical Cancer Prevention and Early Detection". Cancer.
- Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A (2011). "Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: A review of the literature". Gynecological Endocrinology 27 (8): 597–604. doi:10.3109/09513590.2011.558953. PMID 21438669.
- Stuart Campbell; Ash Monga (2006). Gynaecology by Ten Teachers (18 ed.). Hodder Education. ISBN 0-340-81662-7.
- Dillman, edited by Robert K. Oldham, Robert O. (2009). Principles of cancer biotherapy (5th ed.). Dordrecht: Springer. p. 149. ISBN 9789048122899.
- "What Causes Cancer of the Cervix?". American Cancer Society. 2006-11-30. Archived from the original on 2007-10-13. Retrieved 2007-12-02.
- Marrazzo JM, Koutsky LA, Kiviat NB, Kuypers JM, Stine K (2001). "Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women". Am J Public Health 91 (6): 947–52. doi:10.2105/AJPH.91.6.947. PMC 1446473. PMID 11392939.
- "HPV Type-Detect". Medical Diagnostic Laboratories. 2007-10-30. Archived from the original on 2007-09-27. Retrieved 2007-12-02.
- Gottlieb, Nicole (2002-04-24). "A Primer on HPV". Benchmarks. National Cancer Institute. Retrieved 2007-12-02.
- Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ (2003). "Epidemiologic classification of human papillomavirus types associated with cervical cancer". N. Engl. J. Med. 348 (6): 518–27. doi:10.1056/NEJMoa021641. PMID 12571259.
- Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ (2006). "HPV-mediated cervical carcinogenesis: concepts and clinical implications". J. Pathol. 208 (2): 152–64. doi:10.1002/path.1866. PMID 16362994.
- National Institutes of Health, National Cancer Institute: PDQ® Cervical Cancer Prevention. Bethesda, MD: National Cancer Institute. Date last modified 12/17/2015. Accessed 05/20/2015.
- Luhn P, Walker J, Schiffman M, Zuna RE, Dunn ST, Gold MA, Smith K, Mathews C, Allen RA, Zhang R, Wang S, Wentzensen N (2013). "The role of co-factors in the progression from human papillomavirus infection to cervical cancer". Gynecological Oncology 128 (2): 265–270. doi:10.1016/j.ygyno.2012.11.003. ISSN 0090-8258. PMID 23146688.
- Remschmidt C, Kaufmann AM, Hagemann I, Vartazarova E, Wichmann O, Deleré Y (2013). "Risk Factors for Cervical Human Papillomavirus Infection and High-Grade Intraepithelial Lesion in Women Aged 20 to 31 Years in Germany". International Journal of Gynecological Cancer 23 (3): 519–526. doi:10.1097/IGC.0b013e318285a4b2. ISSN 1048-891X. PMID 23360813.
- Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A (2011). "Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature". Gynecological Endocrinology 27 (8): 597–604. doi:10.3109/09513590.2011.558953. ISSN 0951-3590. PMID 21438669.
- Agorastos T, Miliaras D, Lambropoulos AF, Chrisafi S, Kotsis A, Manthos A, Bontis J (2005). "Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions?". European Journal of Obstetrics & Gynecology and Reproductive Biology 121 (1): 99–103. doi:10.1016/j.ejogrb.2004.11.024. ISSN 0301-2115. PMID 15949888.
- Jensen KE, Schmiedel S, Frederiksen K, Norrild B, Iftner T, Kjær SK (2012). "Risk for cervical intraepithelial neoplasia grade 3 or worse in relation to smoking among women with persistent human papillomavirus infection". Cancer Epidemiology, Biomarkers & Prevention 21 (11): 1949–55. doi:10.1158/1055-9965.EPI-12-0663. PMC 3970163. PMID 23019238.
- Cecil Medicine: Expert Consult Premium Edition . ISBN 1437736084, 9781437736083. Page 1317.
- Berek and Hacker's Gynecologic Oncology. ISBN 0781795125, 9780781795128. Page 342
- H. K. Pannu, F. M. Corl & E. K. Fishman (September–October 2001). "CT evaluation of cervical cancer: spectrum of disease". Radiographics 21 (5): 1155–1168. doi:10.1148/radiographics.21.5.g01se311155. PMID 11553823.
- "Cancer Research UK website". Retrieved 2009-01-03.
- DeMay, M (2007). Practical principles of cytopathology. Revised edition. Chicago, IL: American Society for Clinical Pathology Press. ISBN 978-0-89189-549-7.
- Garcia A Hamid O, El-Khoueiry A (2006-07-06). "Cervical Cancer". eMedicine. WebMD. Retrieved 2007-12-02.
- Dolinsky, Christopher (2006-07-17). "Cervical Cancer: The Basics". OncoLink (Abramson Cancer Center of the University of Pennsylvania). Retrieved 2007-12-02.
- Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L (2010). "European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document". Annals of Oncology 21 (3): 448–458. doi:10.1093/annonc/mdp471. PMC 2826099. PMID 20176693.
- Everett T, Bryant A, Griffin MF, Martin-Hirsch PP, Forbes CA, Jepson RG (2011). Everett, Thomas, ed. "Interventions targeted at women to encourage the uptake of cervical screening". Cochrane Database Syst Rev (5): CD002834. doi:10.1002/14651858.CD002834.pub2. PMID 21563135.
- Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L (Mar 2010). "European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document.". Annals of Oncology 21 (3): 448–58. doi:10.1093/annonc/mdp471. PMC 2826099. PMID 20176693.
- "Cervical Cancer Screening Guidelines for Average-Risk Women" (PDF). cdc.gov. Retrieved 8 November 2014.
- "ACOG Practice Bulletin Number 131: Screening for cervical cancer.". Obstetrics and Gynecology 120 (5): 1222–38. Nov 2012. doi:10.1097/AOG.0b013e318277c92a. PMID 23090560.
- Karjane N, Chelmow D (June 2013). "New cervical cancer screening guidelines, again". Obstetrics and Gynecology Clinics of North America 40 (2): 211–23. doi:10.1016/j.ogc.2013.03.001. PMID 23732026.
- Payne N, Chilcott J, McGoogan E (2000). "Liquid-based cytology in cervical screening: a rapid and systematic review". Health Technology Assessment 4 (18): 1–73. PMID 10932023.
- Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N (May 2004). "Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis". Health Technology Assessment 8 (20): iii, 1–78. PMID 15147611.
- "Liquid Based Cytology (LBC): NHS Cervical Screening Programme". Retrieved 2010-10-01.
- Moyer VA (Jun 19, 2012). "Screening for cervical cancer: u.s. Preventive services task force recommendation statement". Annals of Internal Medicine 156 (12): 880–91. doi:10.7326/0003-4819-156-12-201206190-00424. PMID 22711081.
- World Health Organization (2014). Comprehensive cervical cancer control. A guide to essential practice - Second edition. ISBN 978-92-4-154895-3.
- Manhart LE, Koutsky LA (2002). "Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis". Sex Transm Dis 29 (11): 725–35. doi:10.1097/00007435-200211000-00018. PMID 12438912.
- Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, Westenend PJ, Meijer CJ (2003). "Condom use Promotes the Regression of Cervical Intraepithelial Neoplasia and Clearance of HPV: Randomized Clinical Trial". International Journal of Cancer 107 (5): 811–816. doi:10.1002/ijc.11474. PMID 14566832.
- "Semen can worsen cervical cancer". Medical Research Council (UK). Retrieved 2007-12-02.
- Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR (2009). "Efficacy of Human Papillomavirus Vaccines". International Journal of Gynecological Cancer 19 (7): 1166–76. doi:10.1111/IGC.0b013e3181a3d100. PMID 19823051.
- "Human Papillomavirus (HPV) Vaccines: Q & A". Fact Sheets: Risk Factors and Possible Causes. National Cancer Institute (NCI). 2009-10-22. Retrieved 2009-11-11.
- Harper D, Gall S, Naud P, Quint W, Dubin G, Jenkins D; et al. (2008). "Sustained immunogenicity and high efficacy against HPV 16/18 related cervical neoplasia: Long-term follow up through 6.4 years in women vaccinated with Cervarix (GSK's HPV-16/18 AS04 candidate vaccine)". Gynecol Oncol 109: 158–159. doi:10.1016/j.ygyno.2008.02.017.
- "Committee opinion no. 467: human papillomavirus vaccination". Obstet Gynecol 116 (3): 800–3. Sep 2010. doi:10.1097/AOG.0b013e3181f680c8. PMID 20733476.
- The Asahi Shimbun (15 June 2013). "Health ministry withdraws recommendation for cervical cancer vaccine". The Asahi Shimbun.
- Zhang X, Dai B, Zhang B, Wang Z (2011). "Vitamin A and risk of cervical cancer: A meta-analysis". Gynecologic Oncology 124 (2): 366–73. doi:10.1016/j.ygyno.2011.10.012. PMID 22005522.
- Myung SK, Ju W, Kim SC, Kim H (2011). "Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: A meta-analysis". BJOG 118 (11): 1285–91. doi:10.1111/j.1471-0528.2011.03032.x. PMID 21749626.
- Erstad, Shannon (2007-01-12). "Cone biopsy (conization) for abnormal cervical cell changes". WebMD. Retrieved 2007-12-02.
- Jones WB, Mercer GO, Lewis JL, Rubin SC, Hoskins WJ (1993). "Early invasive carcinoma of the cervix". Gynecol. Oncol. 51 (1): 26–32. doi:10.1006/gyno.1993.1241. PMID 8244170.
- Dolson, Laura (2001). "Trachelectomy". Retrieved 2007-12-02.
- Burnett AF (2006). "Radical trachelectomy with laparoscopic lymphadenectomy: review of oncologic and obstetrical outcomes". Curr. Opin. Obstet. Gynecol. 18 (1): 8–13. doi:10.1097/01.gco.0000192968.75190.dc. PMID 16493253.
- Cibula D, Ungár L, Svárovský J, Zivný J, Freitag P (2005). "[Abdominal radical trachelectomy--technique and experience]". Ceska Gynekol (in Czech) 70 (2): 117–22. PMID 15918265.
- Plante M, Renaud MC, Hoskins IA, Roy M (2005). "Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature". Gynecol. Oncol. 98 (1): 3–10. doi:10.1016/j.ygyno.2005.04.014. PMID 15936061.
- Roy M, Plante M, Renaud MC, Têtu B (1996). "Vaginal radical hysterectomy versus abdominal radical hysterectomy in the treatment of early-stage cervical cancer". Gynecol. Oncol. 62 (3): 336–9. doi:10.1006/gyno.1996.0245. PMID 8812529.
- Dargent D, Martin X, Sacchetoni A, Mathevet P (2000). "Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients". Cancer 88 (8): 1877–82. doi:10.1002/(SICI)1097-0142(20000415)88:8<1877::AID-CNCR17>3.0.CO;2-W. PMID 10760765.
- Schlaerth JB, Spirtos NM, Schlaerth AC (2003). "Radical trachelectomy and pelvic lymphadenectomy with uterine preservation in the treatment of cervical cancer". Am. J. Obstet. Gynecol. 188 (1): 29–34. doi:10.1067/mob.2003.124. PMID 12548192.
- Waggoner, Steven E (2003). "Cervical Cancer". The Lancet 361 (9376): 2217–25. doi:10.1016/S0140-6736(03)13778-6.
- "FDA Approves First Drug Treatment for Late-Stage Cervical Cancer". U.S. Food and Drug Administration. 2006-06-15. Retrieved 2007-12-02.
- Sardain, H; Lavoue, V; Redpath, M; Bertheuil, N; Foucher, F; Levêque, J (August 2015). "Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review.". European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 41 (8): 975–85. PMID 25922209.
- "Cervical Cancer". Encyclopedia of Women's Health.
- "What Are the Key Statistics About Cervical Cancer?". American Cancer Society. 2006-08-04. Archived from the original on 2007-10-30. Retrieved 2007-12-02.
- "Cervical Cancer". Cervical Cancer: Cancers of the Female Reproductive System: Merck Manual Home Edition. Merck Manual Home Edition. Retrieved 2007-03-24.
- Committee on Practice Bulletins-Gynecology (2002). "ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas, number 35, May 2002". Obstetrics and gynecology 99 (5 Pt 1): 855–67. PMID 11978302.
- "Cervical Cancer". Cervical Cancer: Pathology, Symptoms and Signs, Diagnosis, Prognosis and Treatment. Armenian Health Network, Health.am.
- (SEER Cancer Statistics Review 1975-2000, National Cancer Institute (NCI)).
- "Cervical cancer statistics and prognosis". Cancer Research UK. Retrieved 2007-03-24.
- Nygård M (2011). "Screening for cervical cancer: When theory meets reality". BMC Cancer 11: 240. doi:10.1186/1471-2407-11-240. PMC 3146446. PMID 21668947.
- "WHO Disease and injury country estimates". World Health Organization. 2009. Retrieved Nov 11, 2009.
- Kent A (Winter 2010). "HPV Vaccination and Testing.". Reviews in Obstetrics and Gynecology 3 (1): 33–4. PMC 2876324. PMID 20508781.
- Howlader (November 10, 2014). "SEER Stat Fact Sheets: Cervix Uteri". National Cancer Institute. Retrieved 7 February 2012.
- SEER cancer statistics
- Armstrong EP (April 2010). "Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types". Journal of Managed Care Pharmacy 16 (3): 217–30. PMID 20331326.
- "Cervical cancer statistics". Cancer Research UK. Retrieved 27 October 2014.
- MacDonald N, Stanbrook MB, Hébert PC (September 2008). "Human papillomavirus vaccine risk and reality". CMAJ (in French) 179 (6): 503, 505. doi:10.1503/cmaj.081238. PMC 2527393. PMID 18762616.
- "Incidence and mortality rates".
- National Cancer Registry Programme under Indian Council of Medical Research Reports
- Krishnatreya, M; Kataki, AC; Sharma, JD; Nandy, P; Gogoi, G (2015). "Association of educational levels with survival in Indian patients with cancer of the uterine cervix.". Asian Pacific Journal of Cancer Prevention 16 (8): 3121–3. PMID 25921107.
- zur Hausen, Harald (2002). "Papillomaviruses and cancer: from basic studies to clinical application". Nature Reviews Cancer 2 (5): 342–350. doi:10.1038/nrc798. ISSN 1474-1768.
- Menczer J (2003). "The low incidence of cervical cancer in Jewish women: has the puzzle finally been solved?" (PDF). Isr. Med. Assoc. J. 5 (2): 120–3. PMID 12674663.
- Heins HC, Dennis EJ, Pratthomas HR (1958). "The possible role of smegma in carcinoma of the cervix". American Journal of Obstetrics & Gynecology 76 (4): 726–33. PMID 13583012.
- Alexander ER (1973). "Possible Etiologies of Cancer of the Cervix Other Than Herpesvirus". Cancer Research 33 (6): 1485–90. PMID 4352386.
- Dürst M, Gissmann L, Ikenberg H, zur Hausen H (1983). "A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions". Proceedings of the National Academy of Sciences of the United States of America 80 (12): 3812–5. doi:10.1073/pnas.80.12.3812. PMC 394142. PMID 6304740..
- Lowy DR, Schiller JT (2006). "Prophylactic human papillomavirus vaccines". J. Clin. Invest. 116 (5): 1167–73. doi:10.1172/JCI28607. PMC 1451224. PMID 16670757.
- McNeil C (April 2006). "Who invented the VLP cervical cancer vaccines?". J. Natl. Cancer Inst. 98 (7): 433. doi:10.1093/jnci/djj144. PMID 16595773. PMID 16595773
- Cancer Institute NSW (2013). "Information about cervical screening for Aboriginal women". NSW Government. Archived from the original on 11 April 2013.
- Mary-Anne Romano (17 October 2011). "Aboriginal cervical cancer rates parallel health inequity". Science Network Western Australia. Archived from the original on 14 May 2013.
- Australian Cervical Cancer Foundation. "Vision and Mission". Australian Cervical Cancer Foundation. Archived from the original on 12 May 2013.
- Australian Cervical Cancer Foundation. "Our People". Australian Cervical Cancer Foundation. Archived from the original on 12 May 2013.
- Gillian Bradford (16 October 2006). "Janette Howard speaks on her battle with cervical cancer". Australian Broadcasting Corporation. Archived from the original on 13 November 2012.
- Tiro JA, Meissner HI, Kobrin S, Chollette V (2007). "What do women in the U.S. know about human papillomavirus and cervical cancer?". Cancer Epidemiol. Biomarkers Prev. 16 (2): 288–94. doi:10.1158/1055-9965.EPI-06-0756. PMID 17267388.
- Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G (2004). "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial". Lancet 364 (9447): 1757–65. doi:10.1016/S0140-6736(04)17398-4. PMID 15541448.
- Peto J, Gilham C, Fletcher O, Matthews FE (2004). "The cervical cancer epidemic that screening has prevented in the UK". Lancet 364 (9430): 249–56. doi:10.1016/S0140-6736(04)16674-9. PMID 15262102.
|Wikimedia Commons has media related to Cervical cancer.|